@article{article, title = {{Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma}}, publisher = {{Ovid Technologies (Wolters Kluwer Health)}}, url = {{}}, year = {{2015}}, month = {{9}}, author = {{Latimer NR and Amonkar MM and Stapelkamp C and Sun P}}, doi = {{10.1097/cmr.0000000000000193}}, volume = {{25}}, journal = {{Melanoma Research}}, issue = {{6}}, pages = {{528-536}}, note = {{Accessed on 2025/04/16}}}